
Daniel Gerlach
@gerlach_d
Associate Scientific Director, Computational Biology Oncology at @boehringer 🧬 Data Scientist & KRAS, MDM2 , HER2 Research. Tweets are my own.
ID: 1325200380
https://www.linkedin.com/in/daniel-gerlach 03-04-2013 18:40:12
8,8K Tweet
1,1K Followers
505 Following


Always great to hear the original RAScal Channing Der Der Lab at UNC talk about KRAS & KRAS inhibitors. Thanks to Channing and his team for putting together such great overview slides. As of March 2025, there are 45 inhibitors (!) & 160 clinical trials. Absolutely amazing. David S. Hong MD


Wow, 160 clinical trials involving agents targeting RAS/KRAS! Norbert Kraut

EGFR mutation is no more a straightforward story. 3 options in 1L, many options in 2L. perez oliveros #ELCC25


#ELCC25 Ph I Daraxonrasib (RAS-On panRAS inhibitor) in RAS+ NSCLC: - ORR 38% - mPFS 9.8m, mDOR 15.1m - modest tox (diarrhea & rash) - 200mg dose selected for ph III Promising. Delighted Ph III RASolve trial of this agent, coming to 🇮🇪 ESMO - Eur. Oncology CancerTrialsIreland 🌈 @Oncoalert #LCSM





T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats G Curigliano MD PhD for leading the DB06 trial that backed this approval! astrazeneca.com/media-centre/p…












I know #AACR25 is coming up, but the program and roster for AACR Special Conference on #PancreaticCancer in Boston in the fall of 2025 is also up and available.... the attendance at this just keeps growing! Dr. Edna Cukierman, Ph.D. Laura DeLong Wood aacr.org/meeting/aacr-s…